ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1106

Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 Neutralizing Antibodies Following BNT162b2 BA.4/5 vs. mRNA-1273 BA.1 Bivalent Vaccination in Hemodialysis Patients and Kidney Transplant Recipients

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Yau, Kevin, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Yuen, Darren A., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Perl, Jeffrey, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Chan, Christopher T., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Levin, Adeera, BC Provincial Renal Agency, Vancouver, British Columbia, Canada
  • Oliver, Matthew J., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Hladunewich, Michelle A., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
Background

Bivalent COVID-19 vaccines are recommended, however differences in neutralization of emerging Omicron subvariants by vaccine type have not been evaluated in patients with kidney disease.

Methods

This was a prospective observational cohort study at three centres in Toronto, Canada from July 25, 2022 to November 30, 2022 in 98 patients receiving hemodialysis or with a kidney transplant. Participants received either the BNT162b2 (original and Omicron BA.4/BA.5) or mRNA-1273 (original and Omicron BA.1) COVID-19 vaccine. Neutralizing antibodies against wild-type, Omicron BA.1, BA.5, BQ.1.1, XBB.1.5 subvariants were measured prior to and one month following the receipt of a bivalent vaccine.

Results

Neutralizing antibodies against BA.1, BA.5, BQ.1.1, and XBB.1.5 increased 8-fold one month following bivalent vaccination. In comparison to wild-type, neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization did not differ by bivalent vaccine type: wild-type (p=0.48), BA.1 (p=0.21), BA.5 (p=0.07), BQ.1.1 (p=0.10), XBB.1.5 (p=0.10).

Conclusion

The BNT162b2 and mRNA-1273 bivalent vaccines induced similar neutralization against all Omicron subvariants in hemodialysis and kidney transplant recipients, suggesting that bivalent vaccines confer protection against emerging Omicron subvariants even if they are antigenically different from the circulating variant.

Neutralizing antibody levels stratified by a) bivalent vaccine type b) anti-nucleocapsid IgG seropositivity c) and hemodialysis versus kidney transplant recipients.

Funding

  • Government Support – Non-U.S.